GUCY1B1 Gene
Introduction
The GUCY1B1 gene (Guanylate Cyclase 1 Soluble Subunit Beta 1) encodes the β₁ subunit of soluble guanylate cyclase (sGC), the primary nitric oxide (NO) receptor in the brain and cardiovascular system. Together with the α₁ subunit encoded by [GUCY1A1](/genes/gucy1a1), GUCY1B1 forms the functional heterodimeric sGC enzyme that catalyzes the conversion of GTP to cyclic GMP (cGMP). This NO-cGMP signaling pathway is fundamental to numerous physiological processes including vasodilation, synaptic plasticity, platelet aggregation, and neuronal survival. In the brain, sGC expressed in neurons, astrocytes, and endothelial cells plays critical roles in neurovascular coupling, learning and memory, and protection against various forms of neuronal injury. Dysregulation of GUCY1B1 and the NO-cGMP pathway has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and various cerebrovascular disorders. [@buche2020]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | GUCY1B1 |
| Full Name | Guanylate Cyclase 1 Soluble Subunit Beta 1 |
| Chromosomal Location | 4q31.3 (proximal to GUCY1A1) |
| NCBI Gene ID | 2983 |
| OMIM ID | 139397 |
| Ensembl ID | ENSG00000147862 |
| UniProt ID | P21452 |
| Protein Class | Enzyme - Guanylate cyclase |
| Aliases | GUCY1B1, sGC-β1, GUCY1B, β1-sGC |
| Gene Family | Soluble guanylate cyclase subunits (GUCY1A1, GUCY1B1) |
</div>
Protein Structure and Function
Structure
...GUCY1B1 Gene
Introduction
The GUCY1B1 gene (Guanylate Cyclase 1 Soluble Subunit Beta 1) encodes the β₁ subunit of soluble guanylate cyclase (sGC), the primary nitric oxide (NO) receptor in the brain and cardiovascular system. Together with the α₁ subunit encoded by [GUCY1A1](/genes/gucy1a1), GUCY1B1 forms the functional heterodimeric sGC enzyme that catalyzes the conversion of GTP to cyclic GMP (cGMP). This NO-cGMP signaling pathway is fundamental to numerous physiological processes including vasodilation, synaptic plasticity, platelet aggregation, and neuronal survival. In the brain, sGC expressed in neurons, astrocytes, and endothelial cells plays critical roles in neurovascular coupling, learning and memory, and protection against various forms of neuronal injury. Dysregulation of GUCY1B1 and the NO-cGMP pathway has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and various cerebrovascular disorders. [@buche2020]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | GUCY1B1 |
| Full Name | Guanylate Cyclase 1 Soluble Subunit Beta 1 |
| Chromosomal Location | 4q31.3 (proximal to GUCY1A1) |
| NCBI Gene ID | 2983 |
| OMIM ID | 139397 |
| Ensembl ID | ENSG00000147862 |
| UniProt ID | P21452 |
| Protein Class | Enzyme - Guanylate cyclase |
| Aliases | GUCY1B1, sGC-β1, GUCY1B, β1-sGC |
| Gene Family | Soluble guanylate cyclase subunits (GUCY1A1, GUCY1B1) |
</div>
Protein Structure and Function
Structure
The GUCY1B1 protein (~619 amino acids) shares structural homology with GUCY1A1 and contains several distinct domains:
- N-terminal regulatory domain: Contains the heme-binding pocket essential for NO sensing. The heme group (Fe(II)-protoporphyrin IX) is bound primarily to the β₁ subunit and is critical for detecting NO
- Dimerization interface: The central region mediates heterodimer formation with GUCY1A1
- C-terminal catalytic domain: Converts GTP to cGMP through a cyclization reaction
The heme iron (Fe²⁺) coordinates NO binding with high affinity, causing a conformational change that dramatically increases catalytic activity. The heme moiety is essential not only for NO sensing but also for maintaining proper protein folding and stability. [@friebe2017]
GUCY1B1 must partner with GUCY1A1 to form a functional enzyme:
- Stoichiometry: 1:1 α₁β₁ heterodimer
- Assembly: Co-translational in the endoplasmic reticulum, requiring both subunits to be present for proper folding and stability
- Stability: The heterodimer is significantly more stable than either homodimer
- Localization: Both cytosolic and membrane-associated fractions, with the heterodimer distributed throughout the cytoplasm and in proximity to the plasma membrane
The physical proximity of the GUCY1A1 and GUCY1B1 genes on chromosome 4q31.3 suggests potential co-regulation at the transcriptional level.
Function
The α₁β₁ sGC heterodimer performs multiple essential functions:
NO sensing: The heme-based detection of NO is the primary activating mechanism. NO binds to the Fe²⁺ of the heme group, causing displacement of the proximal histidine and activation of the catalytic domain
cGMP synthesis: Catalytic conversion of GTP → cGMP, the second messenger that activates downstream effectors
Signal integration: Responds to NO from multiple cellular sources, including neuronal nNOS, endothelial eNOS, and inducible iNOS under inflammatory conditions
Heme-independent activation: Certain sGC stimulators (e.g., cinaciguat, riociguat, vericiguat) can activate sGC independently of NO by binding to the catalytic domainExpression Pattern
GUCY1B1 shows tissue-specific expression with particularly high levels in the cardiovascular and nervous systems:
Brain Expression
- Vascular system: High expression in endothelial cells of cerebral and peripheral blood vessels
- Neurons: Particularly enriched in:
- Cerebral cortex (layer 5 pyramidal neurons)
- Hippocampus (CA1 and CA3 regions)
- Cerebellum (Purkinje cells)
- Basal ganglia ([dopaminergic neurons](/cell-types/dopaminergic-neurons) in substantia nigra and striatum)
- Glia: Moderate expression in astrocytes and microglia
- Choroid plexus: High expression in epithelial cells
Peripheral Expression
- Cardiovascular: High expression in cardiac myocytes, vascular smooth muscle cells, and endothelial cells
- Renal: Expression in tubular epithelial cells
- Hepatic: Expression in hepatocytes
- Pulmonary: Expression in bronchial epithelial cells
In the brain, GUCY1B1 expression is highest during development and decreases with aging, which may contribute to age-related neurodegeneration and reduced neuroplasticity. [@gucyb2020]
Role in Neurodegeneration
Alzheimer's Disease
The NO-cGMP pathway via sGC (GUCY1A1/GUCY1B1) is implicated in multiple aspects of AD pathogenesis:
Amyloid-β effects: Aβ oligomers reduce sGC expression and impair NO-mediated vasodilation in cerebral vessels. This contributes to neurovascular dysfunction and reduced cerebral blood flow observed in AD. Studies show decreased sGC expression in AD temporal cortex and hippocampus. [@modir2020]
Tau pathology interactions: cGMP signaling modulates tau phosphorylation through GSK-3β. Dysregulated sGC activity may contribute to hyperphosphorylated tau accumulation and NFT formation.
Neurovascular unit dysfunction: sGC in endothelial cells regulates blood-brain barrier integrity and neurovascular coupling. Impaired NO-sGC signaling contributes to the breakdown of the neurovascular unit in AD.
Synaptic plasticity deficits: cGMP is essential for long-term potentiation (LTP) and memory formation. sGC dysfunction contributes to the synaptic deficits that correlate with cognitive decline in AD. sGC stimulators have been shown to improve cognitive function in Alzheimer's models. [@gomez2017]
Mitochondrial dysfunction: cGMP signaling modulates mitochondrial biogenesis and function. sGC dysregulation may contribute to the energy deficits observed in AD neurons.Parkinson's Disease
In PD, sGC signaling is affected in multiple ways:
Dopaminergic neuron survival: NO-cGMP signaling protects [dopaminergic neurons](/cell-types/dopaminergic-neurons) from oxidative stress and mitochondrial dysfunction. sGC agonists have shown neuroprotective effects in PD models, preserving dopaminergic neurons in the substantia nigra. [@zhou2019]
Neuroinflammation: sGC activation reduces microglial activation and pro-inflammatory cytokine production. Given the central role of neuroinflammation in PD progression, this represents an important therapeutic target.
Mitochondrial protection: cGMP signaling has anti-oxidant effects and modulates mitochondrial biogenesis through PGC-1α. sGC agonists protect against mitochondrial toxins used in PD models.
α-Synuclein aggregation: Preliminary evidence suggests sGC activation may affect α-synuclein aggregation dynamics.[@tahara2018] demonstrated that sGC is expressed in dopaminergic neurons and modulates their survival and function.
Stroke and Cerebral Ischemia
sGC is a major therapeutic target in stroke:
- Acute neuroprotection: sGC agonists reduce infarct size when administered after ischemia
- Cerebral blood flow: sGC stimulators improve cerebral perfusion through vasodilation
- Excitotoxicity protection: cGMP signaling reduces glutamate-induced excitotoxic damage
- Angiogenesis promotion: sGC activation promotes angiogenesis post-injury
- Blood-brain barrier protection: sGC agonists help maintain BBB integrity post-stroke
[@schmidt2019] and [@koh2018] demonstrate that sGC stimulators have neuroprotective effects in experimental stroke models.
Cerebrovascular Disease
GUCY1B1 mutations or dysregulation are associated with:
Cerebral small vessel disease: sGC dysfunction contributes to vessel wall abnormalities and white matter lesions
Hypertension: sGC in endothelial cells is essential for blood pressure regulation
Vascular cognitive impairment: NO-sGC-cGMP signaling deficits contribute to vascular dementiaSignaling Pathways
Mermaid diagram (expand to render)
Key Downstream Pathways
NO-sGC-cGMP-PKG-CREB: Major pathway for gene transcription regulation
cGMP-CNG channels: Calcium homeostasis and neuronal excitability
cGMP-PDE: Signal termination and cross-talk with cAMP signalingPKG Targets
- CREB (cAMP response element-binding protein)
- DARPP-32
- NMDA receptor subunits
- Synaptic proteins (synapsin, PSD-95)
- Ion channels (L-type Ca²⁺ channels)
Therapeutic Implications
sGC-Targeted Therapies
| Drug | Type | Mechanism | Clinical Status |
|------|------|-----------|-----------------|
| Riociguat | Stimulator | Direct sGC activation | Approved (PAH) |
| Vericiguat | Stimulator | Direct sGC activation | Approved (HF) |
| Cinaciguat | Activator | Heme-independent | Clinical trials |
| IKC-1 | Stimulator | sGC activation | Preclinical (stroke) |
Neuroprotective Strategies
- sGC stimulators protect against cerebral ischemia
- cGMP analogues enhance synaptic plasticity
- PDE5 inhibitors prolong cGMP signaling
- NO donors activate sGC indirectly
- Heme oxygenase modulators affect sGC through heme availability
Challenges
- Blood-brain barrier penetration: Many sGC modulators have limited CNS penetration
- Timing: Optimal window for intervention in disease progression
- Off-target effects: Cardiovascular effects (vasodilation, hypotension)
- Cell-type specificity: Targeting specific brain regions or cell types
[@kim2021] discusses strategies for improving BBB penetration of sGC modulators.
Interactions
Direct Protein Interactions
- [GUCY1A1](/genes/gucy1a1): Primary partner, forms functional sGC heterodimer
- Heme (HEM): Prosthetic group for NO sensing
- PKG1A/PKG1B: Major cGMP effector kinases
- PDE5A: Primary cGMP-metabolizing enzyme in neurons
- Heme oxygenase (HMOX1/2): Modulates heme availability for sGC
Pathway Membership
- Nitric oxide signaling pathway
- cGMP-dependent signaling pathway
- Neurovascular coupling pathway
- Cardiovascular regulation pathway
- Synaptic plasticity pathway
Clinical Significance
Cardiovascular
- Essential for blood pressure regulation through NO-mediated vasodilation
- Target of nitrate-based angina treatments (nitroglycerin, isosorbide dinitrate)
- sGC stimulators approved for pulmonary hypertension and heart failure
Neurological
- Impaired in AD, PD, stroke, and vascular cognitive impairment
- Therapeutic potential in neurodegenerative diseases
- Emerging role in psychiatric disorders (depression, anxiety)
Biomarkers
- sGC expression in peripheral blood cells as a biomarker
- cGMP levels in cerebrospinal fluid
- Genetic variants affecting sGC expression
Animal Models
- Gucy1b1 knockout mice: Viable but show impaired NO-cGMP signaling, hypertension, and increased infarct size after stroke
- Conditional knockouts: Brain-specific deletion reveals roles in synaptic plasticity
- Transgenic models: Overexpression of sGC subunits shows neuroprotection in AD/PD models
- Disease models: sGC agonists effective in various neurodegeneration models
See Also
- [GUCY1A1 Gene](/genes/gucy1a1) - Alpha subunit partner
- [NO Signaling Pathway](/mechanisms/nitric-oxide-signaling)
- [cGMP Signaling Pathway](/mechanisms/cgmp-signaling)
- [Neurovascular Coupling](/mechanisms/neurovascular-coupling)
- [Alzheimer's Disease - Molecular Mechanisms](/diseases/alzheimers-disease)
- [Parkinson's Disease - Molecular Mechanisms](/diseases/parkinsons-disease)
- [Stroke and Neuroprotection](/diseases/stroke)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
External Links
- [NCBI Gene: GUCY1B1](https://www.ncbi.nlm.nih.gov/gene/2983)
- [UniProt: P21452](https://www.uniprot.org/uniprot/P21452)
- [OMIM: 139397](https://www.omim.org/entry/139397)
- [Ensembl: ENSG00000147862](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147862)
References
[Buche J, et al., cGMP signaling and neuroprotection (2020)](https://doi.org/10.1016/j.pneurobio.2020.101893)
[Schmidt M, et al., Soluble guanylate cyclase agonists in stroke therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Evgenov O, et al., NO-independent stimulators of soluble guanylate cyclase (2018)](https://doi.org/10.1111/bph.14501)
[Friebe A, et al., Mechanism of NO/cGMP signaling in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)
[Stasch JP, et al., Targeting soluble guanylate cyclase for therapeutic intervention (2016)](https://doi.org/10.1124/mol.109.061002)
[Derrick M, et al., Role of sGC in perinatal brain injury (2019)](https://doi.org/10.1038/s41598-019-56738-x)
[Koh PO, Soluble guanylate cyclase mediates neuronal death in cerebral ischemia (2018)](https://doi.org/10.3346/jkms.2018.33.e18)
[Gomez L, et al., sGC stimulators improve cognitive function in Alzheimer's models (2017)](https://pubmed.ncbi.nlm.nih.gov/28754210/)
[Takahara K, et al., Soluble guanylate cyclase in dopaminergic neurons (2018)](https://doi.org/10.1007/s00702-018-1850-6)
[Zhou Z, et al., sGC activation protects against Parkinson's disease models (2019)](https://doi.org/10.1038/s41419-019-1656-4)
[Sand A, et al., sGC and neurovascular coupling in aging and AD (2019)](https://doi.org/10.1177/0271678X19836200)
[Iyer P, et al., Heme oxygenase and sGC crosstalk in neurodegeneration (2020)](https://doi.org/10.1016/j.freeradbiomed.2020.01.015)
[Modir F, et al., sGC expression in Alzheimer's disease brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32120294/)
[Russ A, et al., cGMP-dependent protein kinase in synaptic plasticity and memory (2021)](https://doi.org/10.1038/s41583-021-00426-4)
[Kim J, et al., sGC agonists and blood-brain barrier permeability (2021)](https://doi.org/10.1007/s11095-021-06029-9)Pathway Diagram
The following diagram shows the key molecular relationships involving GUCY1B1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)